US 7,396,946 B2 · Compound for treatment of external secretion disorders

Abstract

Disclosed is a method for treatment of external secretion disorders, which comprises administering a fatty 5 acid derivative to a subject in need of said treatment. The method of the present invention is useful for treatment of at least one condition selected from hypolacrimation including disorder of basal tear secretion, dry-eye syndrome, hyposalivation and dry-mouth syndrome.

Claims2

Dependent claims

11-dehydroxy-13,14-dihydro-15-keto-16,16-difluoro-PGE1, or a salt, ether, ester or amide thereof.

Dependencies are inferred from the claim text.

Facts

Application

10/994,364Filed 23 Nov 2004 · division

Priority

14 Jul 1999

Published

US 2005/0090556 A128 Apr 2005

Granted

8 Jul 2008

Term ends

Not estimatedThe source records don’t support an estimate.

Classification23 codes

A61K 31/5575
Eicosanoids, e.g. leukotrienes or prostaglandins: having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
A61K 9/0048
Galenical forms characterised by the site of application: eye, e.g. artificial tears
A61K 9/0056
Mouth and digestive tract, i.e. intraoral and peroral administration: mouth soluble or dispersible forms; Suckable, eatable, chewable coherent…
A61K 31/20
Carboxylic acids, e.g. valproic acid: having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids

Family

Application60/143,627Us provisional application · filed 14 Jul 1999

Application09/615,703Parent of this division · filed 13 Jul 2000

Application10/377,743Parent of this division · filed 4 Mar 2003

US 2005/0090556 A1Pre-grant publication · published 28 Apr 2005

US 6,566,398 B1Parent of this division

US 2003/0171438 A1Published application

US 7,396,946 B2This patent

From the US filing history. Foreign family members aren’t listed.

Abstract

Facts

Application

10/994,364Filed 23 Nov 2004 · division

Priority

14 Jul 1999

Published

US 2005/0090556 A128 Apr 2005

Granted

8 Jul 2008

Term ends

Not estimatedThe source records don’t support an estimate.

Classification23 codes

A61K 31/5575
Eicosanoids, e.g. leukotrienes or prostaglandins: having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
A61K 9/0048
Galenical forms characterised by the site of application: eye, e.g. artificial tears
A61K 9/0056
Mouth and digestive tract, i.e. intraoral and peroral administration: mouth soluble or dispersible forms; Suckable, eatable, chewable coherent…
A61K 31/20
Carboxylic acids, e.g. valproic acid: having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids

Family

Application60/143,627Us provisional application · filed 14 Jul 1999

Application09/615,703Parent of this division · filed 13 Jul 2000

Application10/377,743Parent of this division · filed 4 Mar 2003

US 2005/0090556 A1Pre-grant publication · published 28 Apr 2005

US 6,566,398 B1Parent of this division

US 2003/0171438 A1Published application

US 7,396,946 B2This patent

From the US filing history. Foreign family members aren’t listed.

Compound for treatment of external secretion disorders

Life of this patent

Abstract

Claims2

Compound for treatment of external secretion disorders

Life of this patent

Abstract

Claims2